STLN
The Oncology Institute, Inc.
6.40$
-2.3%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|
| – | – | – | – | -168.5% | – | – | |
| – | +1.2% | -4.5% | -5.3% | -1.0% | +13.7% | – | |
| – | -48.4% | +36.2% | +28.6% | +28.0% | -36.5% | – | |
| – | -205.0% | – | – | -87.9% | +1,440.9% | – | |
| – | +268.3% | -50.0% | +75.5% | -1.7% | -12.9% | – | |
| – | – | – | +75.5% | -1.7% | -12.9% | – | |
| – | -100.0% | -20.0% | +12.5% | +0.0% | -11.1% | – | |
| – | – | +440.0% | -64.8% | -100.7% | +678.6% | – | |
| – | – | – | – | -155.6% | – | – | |
| – | – | – | – | -249.9% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.